Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 71
Filtrar
1.
Eur J Endocrinol ; 184(1): R17-R28, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33112274

RESUMO

ABSTRACT: This review aims to cover the subject of sex steroid action in adolescence. It will include situations with too little sex steroid action, as seen in for example, Turners syndrome and androgen insensitivity issues, too much sex steroid action as seen in adolescent PCOS, CAH and gynecomastia, too late sex steroid action as seen in constitutional delay of growth and puberty and too early sex steroid action as seen in precocious puberty. This review will cover the etiology, the signs and symptoms which the clinician should be attentive to, important differential diagnoses to know and be able to distinguish, long-term health and social consequences of these hormonal disorders and the course of action with regards to medical treatment in the pediatric endocrinological department and for the general practitioner. This review also covers situations with exogenous sex steroid application for therapeutic purposes in the adolescent and young adult. This includes gender-affirming therapy in the transgender child and hormone treatment of tall statured children. It gives some background information of the cause of treatment, the patient's motivation for medicating (or self-medicating), long-term consequences of exogenous sex steroid treatment and clinical outcome of this treatment.


Assuntos
Doenças do Sistema Endócrino/metabolismo , Hormônios Esteroides Gonadais/metabolismo , Puberdade Precoce/metabolismo , Puberdade/metabolismo , Adolescente , Saúde do Adolescente , Doenças do Sistema Endócrino/tratamento farmacológico , Feminino , Hormônios Esteroides Gonadais/uso terapêutico , Humanos , Masculino , Puberdade Precoce/tratamento farmacológico , Adulto Jovem
2.
Science ; 370(6513)2020 10 09.
Artigo em Inglês | MEDLINE | ID: mdl-33033189

RESUMO

In a world powered by intermittent renewable energy, electrolyzers will play a central role in converting electrical energy into chemical energy, thereby decoupling the production of transport fuels and chemicals from today's fossil resources and decreasing the reliance on bioenergy. Solid oxide electrolysis cells (SOECs) offer two major advantages over alternative electrolysis technologies. First, their high operating temperatures result in favorable thermodynamics and reaction kinetics, enabling unrivaled conversion efficiencies. Second, SOECs can be thermally integrated with downstream chemical syntheses, such as the production of methanol, dimethyl ether, synthetic fuels, or ammonia. SOEC technology has witnessed tremendous improvements during the past 10 to 15 years and is approaching maturity, driven by advances at the cell, stack, and system levels.

3.
Scand J Immunol ; 85(6): 450-461, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28370285

RESUMO

In this study, we identified all adults living in Denmark diagnosed with common variable immunodeficiency (CVID) and characterized them according to clinical presentation and EUROclass classification. Using a retrospective, cross-sectional design, possible CVID patients were identified in the Danish National Patient Register and Centers in Denmark treating patients with primary immunodeficiencies. The CVID diagnosis was verified by review of medical records. One-hundred-seventy-nine adults with CVID were identified. This corresponds to a prevalence of 1:26,000. The median age at onset of symptoms was 29 years with no sex difference. The median age at diagnosis was 40 years. Males were diagnosed earlier with a peak in the fourth decade of life, whereas females were diagnosed later with a peak in the sixth decade. The median diagnostic delay was seven years. Recurrent sinopulmonary infections were seen in 92.7% of the patients. The prevalence of non-infectious complications was similar to that of previously reported cohorts: bronchiectasis (35.8%), splenomegaly (22.4%), lymphadenopathy (26.3%), granulomatous inflammation (3.9%) and idiopathic thrombocytopenic purpura (14.5%). Non-infectious complications were strongly associated with B cell phenotype, with all having a reduced number of isotype-switched memory B cells. One-hundred-seventy (95%) were treated with immunoglobulin replacement therapy, primarily administered subcutaneously. According to international guidelines, diagnostic evaluation was inadequate in most cases. This study emphasizes the need for improved diagnostic criteria and more awareness of CVID as a differential diagnosis. Diagnosis and management of CVID patients is a challenge requiring specialists with experience in the field of PID.


Assuntos
Imunodeficiência de Variável Comum/diagnóstico , Imunodeficiência de Variável Comum/terapia , Diagnóstico Tardio , Sistema de Registros/estatística & dados numéricos , Adolescente , Adulto , Idoso , Linfócitos B/imunologia , Linfócitos B/metabolismo , Bronquiectasia/epidemiologia , Imunodeficiência de Variável Comum/epidemiologia , Comorbidade , Estudos Transversais , Dinamarca/epidemiologia , Feminino , Gastroenteropatias/epidemiologia , Testes Genéticos/métodos , Testes Genéticos/estatística & dados numéricos , Humanos , Memória Imunológica/imunologia , Masculino , Pessoa de Meia-Idade , Prevalência , Púrpura Trombocitopênica Idiopática/epidemiologia , Estudos Retrospectivos , Esplenomegalia/epidemiologia , Fatores de Tempo , Adulto Jovem
5.
Acta Anaesthesiol Scand ; 59(10): 1355-66, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26113028

RESUMO

BACKGROUND: Although persons with chronic pain are frequent users of the health care system, they report poor satisfaction with health care services. Participants with persistent opioid use in Nord-Trøndelag Health Study (HUNT)3 report severe pain in spite of treatment. The aim of the study was to test the hypothesis that subjects with persistent opioid use have both a higher consumption of health care services and a poorer satisfaction than the remaining subjects reporting chronic pain. METHODS: This cross-sectional study was based on linkage of self-reported data from the substudy (10,238 were invited, 6927 met the inclusion criteria) of health care use in HUNT3; a population-based health survey during the years 2006-2008 and the complete national registers of the Norwegian Prescription Database and the Cancer Registry of Norway. Patients with chronic pain are stratified according to the level of opioid use as persistent users of opioids, intermittent users, and persons not using opioids. RESULTS: Persons with chronic non-malignant pain reported a higher consumption of all health care services compared to the control group. Consumption of health care services increased with increasing level of opioid use. Persons with persistent opioid use were highly satisfied with all health care services, although less satisfied than persons without chronic pain. CONCLUSIONS: Combined with previous findings of high levels of pain in spite of opioid treatment, the present findings indicate that symptomatic relief is not a prerequisite for patient satisfaction. The study shows higher patient satisfaction compared to previous studies.


Assuntos
Analgésicos Opioides/uso terapêutico , Dor Crônica/tratamento farmacológico , Atenção à Saúde/estatística & dados numéricos , Satisfação do Paciente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Feminino , Humanos , Masculino , Adesão à Medicação , Pessoa de Meia-Idade , Autorrelato
6.
HIV Med ; 12(3): 157-65, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20722752

RESUMO

OBJECTIVE: The aim of the study was to compare changes in bone mineral density (BMD) over 144 weeks in HIV-infected patients initiating nucleoside reverse transcriptase inhibitor (NRTI)-sparing or protease inhibitor-sparing highly active antiretroviral therapy (HAART). METHODS: Sixty-three HAART-naïve patients were randomized to zidovudine/lamivudine+efavirenz or lopinavir/ritonavir+efavirenz. We performed dual energy X-ray absorptiometry (DEXA) at baseline and at weeks 24, 48, 96 and 144 to evaluate lumbar spine and femoral neck (hip) BMD. RESULTS: At baseline, 33 patients (55.9%) had low BMD (T-score < -1.0) and of these eight had osteoporosis (T-score < -2.5). Spine BMD declined in both arms until week 24, before stabilizing. In the NRTI-sparing arm, the mean percentage change from baseline was -2.7% [95% confidence interval (CI) -3.9 to -1.4] at week 24 and -2.5% (95% CI -5.4 to 0.3) at week 144, compared with -3.2% (95% CI -4.4 to -2.1) and -1.9% (95% CI -3.5 to -0.3) in the protease inhibitor-sparing arm. Hip BMD declined until week 48 before stabilizing. In the NRTI-sparing arm, BMD had decreased by -5.1% (95% CI -7.1 to -3.1) at week 48 and -4.5% (95% CI -6.9 to -2.1) at week 144, compared with -6.1% (95% CI -8.2 to -4.0) and -5.0% (95% CI -6.8 to -3.1) in the protease inhibitor-sparing arm. There were no significant differences between arms. Low baseline CD4 cell count was independently associated with spine (P=0.007) and hip (P=0.04) BMD loss and low body mass index with hip BMD loss (P=0.03). CONCLUSION: Spine and hip BMD declined rapidly 24 to 48 weeks after initiating HAART, independent of the assigned drug class, but thereafter BMD values remained stable.


Assuntos
Terapia Antirretroviral de Alta Atividade , Densidade Óssea , Infecções por HIV/tratamento farmacológico , HIV-1 , Absorciometria de Fóton , Adulto , Alcinos , Benzoxazinas/uso terapêutico , Ciclopropanos , Feminino , Humanos , Lamivudina/uso terapêutico , Lopinavir , Masculino , Pirimidinonas/uso terapêutico , Ritonavir/uso terapêutico , Zidovudina/uso terapêutico
7.
Acta Radiol ; 48(2): 145-9, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17354133

RESUMO

Magnetic resonance imaging (MRI) findings in hepatic amyloidosis are not well defined. Here, we report on a patient with renal failure caused by primary amyloidosis (AL type) who developed jaundice. Ultrasound and computed tomography were normal except for some ascites. MRI with oral manganese-containing contrast agent revealed several focal areas without contrast uptake in the hepatocytes and no bile secretion after 8 hours. No extrahepatic bile obstructions were found. Liver biopsy showed severe intraportal, vascular, and parenchymal amyloidosis causing severe cholestasis and atrophy of hepatocytes.


Assuntos
Amiloidose/diagnóstico , Colangiopancreatografia por Ressonância Magnética , Colestase Intra-Hepática/diagnóstico , Manganês , Atrofia , Biópsia , Meios de Contraste , Diagnóstico Diferencial , Evolução Fatal , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Ultrassonografia de Intervenção
8.
Int J Obes (Lond) ; 31(3): 449-56, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16847472

RESUMO

OBJECTIVE: Lipodystrophy is the major complication of antiretroviral therapy in HIV-infected patients. Its pathophysiology is not well understood, but has been linked to antiadipogenic effects of antiretroviral drugs. Lipin represents a newly characterized protein that is critical for adipocyte differentiation, and lipin deficiency leads to lipodystrophy in the mouse. The objective of this study was to determine whether altered lipin gene expression is associated with HIV lipodystrophy in humans. DESIGN: We measured lipin mRNA levels in subcutaneous abdominal and femoral-gluteal adipose tissue biopsies from HIV-infected patients with or without lipodystrophy, and in healthy controls. Real-time reverse transcription-PCR was performed to quantitate total lipin expression levels, and expression of two lipin isoforms (lipin-alpha and -beta) that are generated by alternative mRNA splicing. RESULTS: As predicted from studies with mice, lipin mRNA levels were correlated with limb fat mass in HIV patients, with lower lipin levels in patients with lipodystrophy than those without lipodystrophy. Unexpectedly, however, this was explained by an increase in lipin-beta expression in HIV patients without lipodystrophy compared to patients with lipodystrophy and control subjects. In addition, lipin expression levels were inversely correlated with adipose tissue expression of inflammatory cytokines interleukin (IL)-6, IL-8 and IL-18, which typically increase in HIV-associated lipoatrophy. CONCLUSIONS: Elevated lipin expression levels are associated both with the maintenance of greater fat mass and lower cytokine expression in HIV-infected patients. Based on the demonstrated role for lipin in promoting lipogenic gene expression, these observations raise the possibility that variations in lipin levels may contribute to variations in adipose tissue mass and function that distinguish HIV patients with and without lipodystrophy.


Assuntos
Tecido Adiposo/metabolismo , Infecções por HIV/metabolismo , Proteínas Nucleares/análise , Estudos Transversais , Extremidades , Expressão Gênica/genética , Infecções por HIV/genética , Síndrome de Lipodistrofia Associada ao HIV/genética , Síndrome de Lipodistrofia Associada ao HIV/metabolismo , Humanos , Interleucinas/análise , Isomerismo , Masculino , Pessoa de Meia-Idade , Fosfatidato Fosfatase , RNA Mensageiro/análise , Fator de Necrose Tumoral alfa/análise
9.
Clin Genet ; 69(3): 277-83, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16542394

RESUMO

The lipid disorder familial hypercholesterolemia (FH) predisposes to cardiovascular disease. With a prevalence of approximately one in 500 in the general Caucasian population, FH is one of the most frequent single-gene disorders. As the mutational spectra vary between populations, it is crucial to identify the mutations in a given population in order to implement a molecular genetic screening strategy. A total of 1053 referred individuals with clinical signs of FH were investigated, and mutations were identified in 425 individuals. Fifty-four different mutations were identified, of which 13 are novel. The five most frequent mutations accounted for 56.3% of all disease-causing mutations. The majority of the remaining mutations were of a private nature only encountered in single families. In this study, a reliable molecular genetic screening protocol was established, and the relevance of performing presymptomatic genetic analysis as part of a preventive strategy was documented. We have acquired knowledge of the mutational spectra in the Danish population and thus will be able to trace mutations in their relatives through our index cases.


Assuntos
Hiperlipoproteinemia Tipo II/genética , Apolipoproteína B-100 , Apolipoproteínas B/genética , Dinamarca , Feminino , Testes Genéticos , Humanos , Hiperlipoproteinemia Tipo II/sangue , Masculino , Biologia Molecular , Mutação , Receptores de LDL/genética
10.
HIV Med ; 7(1): 38-45, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16313291

RESUMO

OBJECTIVES: To establish the prevalence and quantify the severity of body fat redistribution and dyslipidaemia in HIV-infected men after long-term highly active antiretroviral therapy (HAART) compared with the background population. METHODS: In a cross-sectional study, we included 87 HIV-infected men who had received HAART for at least 6 years and 34 HIV-negative men. Regional body composition was assessed using dual-energy X-ray absorptiometry. Fasting metabolic parameters were obtained. Associations between regional body fat distribution and metabolic parameters were evaluated. RESULTS: HIV-infected patients and controls did not differ with regard to height and lean body mass. Compared with controls, HIV-infected men had reduced total fat mass (median 12.3 versus 19.2 kg, P<0.001), limb fat mass (4.3 versus 7.9 kg, P<0.001), and trunk fat mass (6.7 versus 10.8 kg, P<0.001) and higher trunk/limb fat ratio (1.7 versus 1.2, P<0.001). Also, patients without clinical lipodystrophy had reduced amounts of limb and trunk fat. In HIV-infected men, triglyceride levels were higher (2.0 versus 1.2 mmol/L, P<0.001), high-density lipoprotein (HDL)-cholesterol levels were lower (1.2 versus 1.3 mmol/L, P<0.05) and insulin levels were higher (40.8 versus 29.9 pmol/L, P<0.01) than in controls. All adverse metabolic parameters correlated with increased trunk/limb fat ratio, and insulin levels correlated positively with trunk fat mass (P<0.01). CONCLUSION: Peripheral as well as central fat loss is a general characteristic of HIV-infected men after long-term HAART. Although lipoatrophy was the dominant morphological presentation, the adverse metabolic parameters were mainly associated with the increased ratio of trunk/limb fat.


Assuntos
Fármacos Anti-HIV/efeitos adversos , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Síndrome de Lipodistrofia Associada ao HIV/induzido quimicamente , Absorciometria de Fóton , Adulto , Antropometria , Composição Corporal/efeitos dos fármacos , Distribuição da Gordura Corporal , Estudos Transversais , Extremidades/patologia , Infecções por HIV/sangue , Infecções por HIV/tratamento farmacológico , Infecções por HIV/patologia , Síndrome de Lipodistrofia Associada ao HIV/sangue , Síndrome de Lipodistrofia Associada ao HIV/patologia , Humanos , Insulina/sangue , Ácido Láctico/sangue , Lipídeos/sangue , Masculino , Pessoa de Meia-Idade , Relação Cintura-Quadril
11.
J Infect Dis ; 190(11): 1947-56, 2004 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-15529259

RESUMO

OBJECTIVE: The purpose of the present study was to determine the prevalence and incidence of virological triple drug-class failure (TCF) and to summarize the clinical outcome for patients who started receiving highly active antiretroviral therapy (HAART). METHODS: The present study is an observational longitudinal study of 3496 treatment-experienced (TE) and treatment-naive (TN) patients monitored from the time they started receiving HAART (baseline) until TCF occurred (as determined on the basis of viral loads), until AIDS was newly diagnosed, or until death. RESULTS: Four hundred forty-five patients (12.7%) had TCF; 370 (16.6%) of 2230 patients were TE, and 75 (5.9%) of 1266 patients were TN. At 6 years after starting HAART, 21.4% of TE and 11.2% of TN patients had TCF (P<.0001). The prevalence of TCF at or after 2002 was 15.5% in TE patients and 4.8% in TN patients. TN patients had a 32% annual increase in the incidence of TCF (95% confidence interval [CI], 14%-54%; P<.0001); at 5 years after starting HAART, the rate was comparable for TE and TN patients (3.3 and 3.4 cases/100 person-years of follow-up [PYFU], respectively). The incidence of new cases of AIDS or death was 2.7 cases/100 PYFU in patients who did not experience TCF and 5.0 cases/100 PYFU in patients who did experience TCF, an estimated 36% increase with each category of TCF (95% CI, 19%-56%; P<.0001). CONCLUSION: The prevalence of TCF was low after patients started receiving HAART, particularly among TN patients. Despite the influx of patients who had started receiving HAART more recently, the prevalence of TCF increased over calendar time. Patients with TCF had a higher incidence of newly diagnosed AIDS or death. Treatment of patients with TCF deserves further investigation.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/tratamento farmacológico , HIV-1 , Síndrome da Imunodeficiência Adquirida/epidemiologia , Síndrome da Imunodeficiência Adquirida/mortalidade , Terapia Antirretroviral de Alta Atividade , Contagem de Linfócito CD4 , Estudos de Coortes , Intervalos de Confiança , Europa (Continente)/epidemiologia , Feminino , Seguimentos , Infecções por HIV/epidemiologia , Humanos , Incidência , Masculino , Prevalência , Fatores de Tempo , Falha de Tratamento , Carga Viral
12.
Allergy ; 59(1): 45-53, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14674933

RESUMO

BACKGROUND: Both sublingual allergen-specific immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) have a documented clinical efficacy, but only few comparative studies have been performed. OBJECTIVE: To investigate the clinical efficacy of SLIT vs SCIT and secondary to compare SLIT and SCIT with placebo and to evaluate the relative clinical efficacy in relation to systemic side-effects. METHODS: A 3-year randomized, placebo-controlled, double-blind, double-dummy study including 71 adult birch pollen hay fever patients treated for two consecutive years after a baseline year. Allocation to treatment groups was based on disease severity in the baseline season, gender and age. RESULTS: Clinical efficacy was estimated in 58 patients completing the first treatment year by subtracting baseline data and by calculating the ratio first treatment season vs baseline. SLIT diminished the median disease severity to one-half and SCIT to one-third of placebo treatment. No statistical significant difference between the two groups was observed. Both for symptoms and medication scores actively treated patients showed statistically significant and clinical relevant efficacy compared with placebo. SLIT treatment only resulted in local mild side-effects, while SCIT resulted in few serious systemic side-effects. CONCLUSION: Based on the limited number of patients the clinical efficacy of SLIT was not statistically different from SCIT, and both treatments are clinically effective compared with placebo in the treatment of birch pollen rhinoconjunctivitis. The lack of significant difference between the two treatments does not indicate equivalent efficacy, but to detect minor differences necessitates investigation of larger groups. Due to the advantageous safety profile SLIT may be favored.


Assuntos
Betula/imunologia , Dessensibilização Imunológica/métodos , Pólen/imunologia , Rinite Alérgica Sazonal/terapia , Administração Sublingual , Adulto , Alérgenos/imunologia , Alérgenos/farmacologia , Antialérgicos/administração & dosagem , Estudos Cross-Over , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Probabilidade , Valores de Referência , Rinite Alérgica Sazonal/etiologia , Medição de Risco , Estatísticas não Paramétricas , Resultado do Tratamento
13.
APMIS ; 109(12): 849-56, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11846726

RESUMO

To date, immunosuppressive therapy for allograft rejection is based on a generalized inhibition of the recipient's T cells, rendering the individual less resistant to infections and malignancies. In order to change this therapeutic approach towards the induction of specific transplant tolerance, it is essential to identify the cells and molecular pathways involved in direct allorecognition. An in vitro model with interferon-gamma (IFN-gamma)-stimulated human lung microvascular endothelial cells (HMVEC-L) as targets and allogenic T cells as responders was used to identify donor cells for recipient cellular immunorecognition. HMVEC-L activated purified allogenic T cells in cocultures. This activation was partly mediated by lymphocyte function antigen-3 (LFA-3), but not CD86, as shown by monoclonal antibody (mAb) inhibition. This finding was supported by the expression of LFA-3 antigen, but not CD86, on IFN-gamma-stimulated HMVEC-L. Surprisingly, even in the absence of T-cell proliferation, T cells were capable of enhancing LFA-3 antigen, but not CD86 expression on HMVEC-L. In conclusion, HMVEC-L are capable of direct allostimulation of human T cells, partly through an LFA-3-dependent costimulatory pathway. Since ICAM-1 expression on HMVEC is greatly enhanced by IFN-gamma and T cell coculturing, this molecule may serve as an additional costimulator. A reciprocal HMVEC-L stimulation by allogenic T-cells occurs, even without T-cell proliferation, possibly representing a preproliferative phase. Since this study included a single target as well as responder cell donor, further studies with multiple donors are needed to evaluate possible variations.


Assuntos
Antígenos CD/fisiologia , Antígenos CD58/fisiologia , Endotélio Vascular/citologia , Pulmão/irrigação sanguínea , Ativação Linfocitária , Glicoproteínas de Membrana/fisiologia , Linfócitos T/imunologia , Antígeno B7-2 , Células Cultivadas , Técnicas de Cocultura , Endotélio Vascular/fisiologia , Humanos , Imuno-Histoquímica , Molécula 1 de Adesão Intercelular/análise , Monócitos/química , Linfócitos T/química
14.
Br J Dermatol ; 142(6): 1160-5, 2000 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10848740

RESUMO

Results of ultraviolet (UV) B phototherapy can be improved by the application of calcipotriol, but studies are needed to decide how the two treatments should be combined. We studied the effect of UVB after application of calcipotriol ointment (50 microg g-1) and calcipotriol cream (50 microg g-1) and determined the optimal time of application of calcipotriol when combined with UVB phototherapy (280-350 nm), in a single-blinded randomized vehicle-controlled study of 37 healthy adult volunteers. Calcipotriol ointment or cream was applied randomly on five areas on the back at different time intervals from UVB irradiation. One area was left untreated as the control. Application times were the evening before, the morning before, 2 h before, immediately before, and immediately after irradiation. UVB irradiation was administered by TL20W/12 fluorescent tube lamps at increasing doses (20, 25, 32, 40, 50 and 64 mJ cm-2) to six subunits of each test area. Clinical assessment was performed 24 h after UVB irradiation by a blinded investigator. Calcipotriol ointment and cream were applied in 19 and 18 subjects, respectively, and erythema was measured for each application time quantified. We found that erythemal reactions were significantly smaller when calcipotriol ointment or cream was applied immediately before irradiation compared with all other application times. To explain these findings, a vehicle control study was performed. No difference in erythema was seen between calcipotriol medication and the vehicle controls. Spectrophotometric analysis of the calcipotriol cream and ointment showed no UV absorbance in the UVB range. No signs of photosensitization were noted. In conclusion, the vehicles of the calcipotriol ointment and cream inhibit the induction of erythema by UVB irradiation if applied immediately before phototherapy. Consequently, calcipotriol ointment and cream should not be applied directly before UVB irradiation; however, they may be applied at any time up to 2 h prior to or immediately after UVB irradiation. Possible explanations for this sunscreen activity are discussed.


Assuntos
Calcitriol/análogos & derivados , Fármacos Dermatológicos/administração & dosagem , Eritema/prevenção & controle , Lesões por Radiação/prevenção & controle , Terapia Ultravioleta/efeitos adversos , Adolescente , Adulto , Calcitriol/administração & dosagem , Calcitriol/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Esquema de Medicação , Portadores de Fármacos , Eritema/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas , Veículos Farmacêuticos/administração & dosagem , Doses de Radiação , Lesões por Radiação/etiologia , Método Simples-Cego
15.
J Perinat Med ; 28(2): 97-103, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10875093

RESUMO

In order to find a reliable early marker of infection in newborns a study with simultaneous determination of soluble Intercellular Adhesion Molecule-1 (sICAM-1) and C-Reactive Protein (CRP) was planned. Prospectively 90 babies < 5 days of age suspect of infection were included. Retrospectively this population was classified into an "infected" group (n = 45) and a "non-infected" group (n = 45). For each of these two groups we calculated the sensitivity, specificity and predictive values of sICAM-1 and CRP as early markers of infection. We determined the best cut-off level for sICAM-1 to be 300 micrograms/l and for CRP 5 mg/l. As a biochemical test for infection in the newborns the sensitivity and negative predictive value for CRP were 0.69 and 0.73 respectively. When sICAM-1 was added and CRP and s-ICAM-1 were used in combination the sensitivity improved significantly to 0.93, p < 0.01 and the negative predictive value improved to 0.92, p < 0.05. In normal 5-8 days old babies' sICAM-1 was significantly higher than at birth (cord blood), p < 0.0001. In conclusion, sICAM-1 and CRP in combination are better than CRP as a primary test for identification of infection in babies < 5 days of age.


Assuntos
Biomarcadores/sangue , Proteína C-Reativa/análise , Infecções/diagnóstico , Molécula 1 de Adesão Intercelular/sangue , Humanos , Recém-Nascido , Infecções/sangue , Pneumonia Bacteriana/sangue , Pneumonia Bacteriana/diagnóstico , Valores de Referência , Sepse/sangue , Sepse/diagnóstico , Viroses/sangue , Viroses/diagnóstico
17.
Acta Ophthalmol Scand ; 77(3): 331-5, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10406156

RESUMO

PURPOSE: To evaluate possible changes in aetiology and frequency of bulbar eviscerations and enucleations. METHODS: A total of 1028 cases from three two-year periods: 1975-76, 1985-86 and 1995-96 collected by the Eye Pathology Institute were reviewed. RESULTS: A significant decrease (p<0.001) in number of enucleations was observed from 358 in 1975-76 to 214 in 1995-96, corresponding to an almost equivalent increase in number of eviscerations from 5 in 1975-76 to 83 in 1995-96. The total number of eye removals decreased significantly (p<0.01) over the last two periods from 368 in 1985-86 to 296 in 1995-96. This was primarily caused by a decrease in the number of glaucoma-related enucleations from 32.7% in 1975-76 to 15.0% in 1995-96. The reduction in number was not fully balanced by the increase in glaucoma-related eviscerations. CONCLUSION: Over the last 20 years there has been a change in choice of operation from enucleation to evisceration.


Assuntos
Oftalmopatias/epidemiologia , Enucleação Ocular/estatística & dados numéricos , Evisceração do Olho/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Dinamarca/epidemiologia , Oftalmopatias/etiologia , Oftalmopatias/cirurgia , Feminino , Seguimentos , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
19.
Clin Genet ; 53(6): 433-9, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9712531

RESUMO

We have recently developed a simple mutation screening assay based on the denaturing gradient gel electrophoresis (DGGE) technique for detection of mutations in the coding and regulatory regions of the low density lipoprotein receptor (LDLR) gene and the codon 3500 region of the apolipoprotein (apo) B-100 gene leading to familial hypercholesterolemia (FH) and familial defective apo B-100 (FDB), respectively. To evaluate the assay, 14 Danish families suspected of FH were studied. In ten families, the DGGE assay detected seven different point mutations, including mutations undescribed prior to establishing the assay. In addition, in one of these ten families and in one of the remaining four families, Southern blotting detected the FH-DK3 exon 5 deletion. Based on segregation analysis and clinical data, the FH diagnosis was dubious in the remaining three families without DGGE or Southern blotting detectable mutations. In conclusion, a simple DGGE based mutation screening assay may detect underlying mutations in most FH/FDB families, thus allowing its routine use in genetic counselling of FH-families.


Assuntos
Apolipoproteínas B/deficiência , Apolipoproteínas B/genética , Eletroforese/métodos , Testes Genéticos/métodos , Hiperlipoproteinemia Tipo II/genética , Mutação , Receptores de LDL/genética , Animais , Apolipoproteína B-100 , Cricetinae , Cricetulus , Estudos de Avaliação como Assunto , Éxons , Humanos , Camundongos , Ratos , Xenopus laevis
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA